MBX (MBX Biosciences) Ending Cash Position: $45.42 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MBX MBX Biosciences Inc MBX
12 GF Score
Price $58.32
! 2 Warning Signs
View Full Analysis

What is MBX Biosciences Ending Cash Position?

MBX Biosciences MBX -3.87% 12 Ending Cash Position is $45.42 Mil as of Mar. 2026. GuruFocus rates MBX with a GF Score™ of 12/100. The stock has 2 warning signs investors should review.

MBX Biosciences's Ending Cash Position for the quarter that ended in Mar. 2026 was $45.42 Mil.

MBX Biosciences's quarterly Ending Cash Position declined from Sep. 2025 ($223.13 Mil) to Dec. 2025 ($75.29 Mil) and declined from Dec. 2025 ($75.29 Mil) to Mar. 2026 ($45.42 Mil).

MBX Biosciences's annual Ending Cash Position increased from Dec. 2023 ($30.52 Mil) to Dec. 2024 ($49.35 Mil) and increased from Dec. 2024 ($49.35 Mil) to Dec. 2025 ($75.29 Mil).

MBX Biosciences Ending Cash Position Related Terms

MBX Biosciences Ending Cash Position Historical Data

* Premium members only.

The historical data trend for MBX Biosciences's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MBX Biosciences Ending Cash Position Chart

MBX Biosciences Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Ending Cash Position
24.21 30.52 49.35 75.29

MBX Biosciences Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29.90 39.78 223.13 75.29 45.42
MBX
12GF Score
MBX Biosciences Inc MBX
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MBX Biosciences Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

MBX Biosciences's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=49.351+25.938
=75.29

MBX Biosciences's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=75.289+-29.87
=45.42

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $45.42 Mil mean?
MBX Biosciences (MBX) has a Ending Cash Position of $45.42 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on MBX Biosciences and its competitors.
Is MBX Biosciences' Ending Cash Position too high?
MBX Biosciences' current Ending Cash Position is $45.42 Mil. Overall, MBX Biosciences has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does MBX Biosciences' Ending Cash Position compare to SLS and TRVI?
MBX Biosciences' Ending Cash Position of $45.42 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on MBX Biosciences and its competitors. MBX Biosciences's current Ending Cash Position is $45.42 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MBX Biosciences stock overvalued right now?
MBX Biosciences (MBX) has a current Ending Cash Position of $45.42 Mil. The current Ending Cash Position is $45.42 Mil. MBX Biosciences' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For MBX Biosciences (MBX), the current Ending Cash Position is $45.42 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MBX Biosciences Business Description

Address 11711 N. Meridian Street, Suite 300, Carmel, IN, USA, 46032
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.
12GF Score

Get the complete analysis for MBX

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$58.32
Price